Arbutus Biopharma Corporation ABUS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Arbutus Biopharma Corporation’s reported figures.
Based on trailing twelve months.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's return on equity?
- Arbutus Biopharma Corporation (ABUS) reported return on equity of 94.7% in Q1 2026.
- How has Arbutus Biopharma Corporation's return on equity changed year-over-year?
- Arbutus Biopharma Corporation's return on equity increased by 219.9% year-over-year, from -79% to 94.7%.
- What is the long-term trend for Arbutus Biopharma Corporation's return on equity?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's return on equity has grown at a -12.0% compound annual growth rate (CAGR), from -73% to -38.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.